Track the Dr. Lal Pathlabs stock price and the full directors' dealings record of the company, a publicly traded company based in India. Shares are quoted on the IN market, under the authority of SEBI (PIT + SAST). Market capitalisation: €317.8bn. The latest transaction was reported on 21 September 2026 (Acquisition). Among the most active insiders: Amit Aggarwal. The full history is accessible without an account.
101
Insider Decl.
n/a
Thresholds
€3m
40 ops.
Buy Volume
€8m
61 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Dr. Lal Pathlabs Buy (bullish), based on 26 analysts. Average price target: ₹1,949.23.
39Σ signal
Buys €3m€8m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,913 of 29,156 companies
59.5
score / 100
Value
32
Quality
87
FCF yld1.4%
Earn yld1.6%
EV/EBITDA37.8x
ROE21%
Gross mgn81%
Net mgn18%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
1,000 shares@ ₹1,972.600.0006% mcap11.6% of flowEquityMarket SaleSEBI:f2499f41760e7f3238420c76de65776552b91d8f
25 of 101 declarations
About Dr. Lal Pathlabs
Dr. Lal Pathlabs is an Indian company specializing in medical diagnostic services. It offers a wide range of laboratory tests for patients and healthcare institutions.